Senicapoc

Summary

Senicapoc (CHEMBL405821) is a phase-3 clinical-stage small molecule targeting KCNN4; indicated across 4 conditions including sickle cell disease and severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (KCNN4)
• Indications: 4 conditions
• Clinical trials: 9
• Chemistry: 323.3 Da · C20H15F2NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL405821
Name	Senicapoc
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	216327
Molecular formula	C20H15F2NO
Molecular weight	323.3
InChIKey	SCTZUZTYRMOMKT-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N

IUPAC name: 2,2-bis(4-fluorophenyl)-2-phenylacetamide

Also known as: ICA-17043, PF-05416266, Senicapoc, SENICAPOC

Patent coverage: 72 distinct patent families (164 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
KCNN4	KCa3.1	Inhibition	7.96	0.2%	O15554

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Intermediate conductance calcium-activated potassium channel protein 4.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNN4	8.22	IC50	6	nM	CHEMBL_ACT_12662662
KCNN4	7.92	IC50	12	nM	CHEMBL_ACT_2102131

Target pathways

Aggregated over 1 target gene(s): KCNN4.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Neuronal System	1	KCNN4
Ca2+ activated K+ channels	1	KCNN4
Potassium Channels	1	KCNN4

Dominant GO biological processes

GO term	Targets
immune system process	1
potassium ion transport	1
calcium ion transport	1
cell volume homeostasis	1
defense response	1
stabilization of membrane potential	1
macropinocytosis	1
phospholipid translocation	1
saliva secretion	1
positive regulation of protein secretion	1
positive regulation of T cell receptor signaling pathway	1
protein homotetramerization	1
establishment of localization in cell	1
potassium ion transmembrane transport	1
positive regulation of potassium ion transmembrane transport	1

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
sickle cell disease	3	MONDO:0011382	MONDO:0011382
severe acute respiratory syndrome	2	MONDO:0005091	EFO:0000694
asthma	2	MONDO:0004979	MONDO:0004979

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00102791	PHASE3	TERMINATED	A Stratified Sickle Event Randomized Trial (ASSERT)
NCT00294541	PHASE3	TERMINATED	A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy
NCT04804241	PHASE2	RECRUITING	Senicapoc in Alzheimer’s Disease
NCT06714123	PHASE2	RECRUITING	Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
NCT07282210	PHASE2	NOT_YET_RECRUITING	Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
NCT00861185	PHASE2	COMPLETED	Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma
NCT00861211	PHASE2	COMPLETED	Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects
NCT04594668	PHASE2	UNKNOWN	Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
NCT07284069	EARLY_PHASE1	RECRUITING	Senicapoc and Perampanel for Newly Diagnosed Glioblastoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

3 molecules share ≥1 primary target. Top 3 by shared-target count:

Molecule	Source	Status	Shared targets
CLOTRIMAZOLE	ChEMBL + PubChem	Phase 4 (approved)	KCNN4
Chlorzoxazone	PubChem	Approved	KCNN4
Riluzole	PubChem	Approved	KCNN4